{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:41:11Z","timestamp":1761871271954,"version":"build-2065373602"},"reference-count":13,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.clml.2018.12.014","type":"journal-article","created":{"date-parts":[[2019,1,2]],"date-time":"2019-01-02T02:17:33Z","timestamp":1546395453000},"page":"251-254","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial"],"prefix":"10.1016","volume":"19","author":[{"given":"Rami S.","family":"Komrokji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Najla H.","family":"Al Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Padron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5422-6863","authenticated-orcid":false,"given":"Christopher","family":"Cogle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Tinsley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Sallman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey E.","family":"Lancet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan F.","family":"Lis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2018.12.014_bib1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11899-011-0086-x","article-title":"Management of lower-risk myelodysplastic syndromes: the art and evidence","volume":"6","author":"Komrokji","year":"2011","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.clml.2018.12.014_bib2","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","article-title":"Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion","volume":"355","author":"List","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.12.014_bib3","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1182\/blood-2007-01-068833","article-title":"Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q","volume":"111","author":"Raza","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.12.014_bib4","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1182\/blood.V124.21.409.409","volume":"124","author":"Santini","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.12.014_bib5","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1182\/blood-2010-11-318543","article-title":"Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis","volume":"118","author":"Narla","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.12.014_bib6","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.12.014_bib7","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nature06494","article-title":"Identification of RPS14 as a 5q\u2212 syndrome gene by RNA interference screen","volume":"451","author":"Ebert","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.clml.2018.12.014_bib8","doi-asserted-by":"crossref","first-page":"12974","DOI":"10.1073\/pnas.0811267106","article-title":"A\u00a0critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide","volume":"106","author":"Wei","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2018.12.014_bib9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature14610","article-title":"Lenalidomide induces ubiquitination and degradation of CK1alpha in del(5q) MDS","volume":"523","author":"Kronke","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.clml.2018.12.014_bib10","doi-asserted-by":"crossref","first-page":"e114249","DOI":"10.1371\/journal.pone.0114249","article-title":"Lenalidomide induces lipid raft assembly to enhance erythropoietin receptor signaling in myelodysplastic syndrome progenitors","volume":"9","author":"McGraw","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2018.12.014_bib11","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2012-03-415661","article-title":"Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome","volume":"120","author":"Komrokji","year":"2012","journal-title":"Blood"},{"issue":"suppl","key":"10.1016\/j.clml.2018.12.014_bib12","doi-asserted-by":"crossref","first-page":"7002","DOI":"10.1200\/jco.2013.31.15_suppl.7002","article-title":"A\u00a0randomized study of lenalidomide (LEN) with or without EPO in RBC transfusion dependent (TD) IPSS low and int-1 (lower risk) myelodysplastic syndromes (MDS) without del 5q resistant to EPO","volume":"15","author":"Toma","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.12.014_bib13","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1182\/blood.V128.22.223.223","volume":"128","author":"List","year":"2016","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018311935?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018311935?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:32:32Z","timestamp":1761870752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265018311935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S2152265018311935"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2018.12.014","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2018.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}